Showing 5111-5120 of 5353 results for "".
- District Court Judge Blocks Marketing and Sales of RevitaLashhttps://practicaldermatology.com/news/20130320-district_court_judge_blocks_marketing_and_sales_of_revitalash/2459584/A district court judge recently prohibited Athena Cosmetics, Inc. from marketing or selling its RevitaLash Advanced Eyelash Conditioner in the United States. The ruling came as part of a civil lawsuit brought by Allergan Inc., maker of Latisse, in which the company claimed unfair competition in the
- On Match Day, AMA Calls for Additional Residency Positions to Address Physician Shortagehttps://practicaldermatology.com/news/20130319-on_match_day_ama_calls_for_additional_residency_positions_to_address_physician_shortage/2459585/A statement released by Jeremy A. Lazarus, M.D., President of the American Medical Association, is seeking to raise awareness about the physician shortage. "Today, on Match Day, thousands of medical students will learn where they will complete their graduate medical education (GME), known as reside
- NeoStrata Introduces Line Lift Duohttps://practicaldermatology.com/news/20130314-neostrata_introduces_line_lift_duo/2459589/NeoStrata Company, Inc. launched the SKIN ACTIVE Line Lift featuring Aminofil™, a novel tyrosine amino acid derivative (N-Acetyl Tyrosinamide) that delivers a rapid volumizing effect in the deep skin matrix to visibly reduce deep facial lines and wrinkles. Applied together twice daily, the SKIN ACTI
- Dermablend Launches Concealer and Highlighter for Clearer Complexionhttps://practicaldermatology.com/news/20130314-dermablend_launches_concealer_and_highlighter_for_clearer_complexion/2459590/Dermablend's new Quick-Fix Illuminator is a multi-purpose concealer and highlighter that can conceal, smooth, illuminate, brighten, highlight and sculpt the face for an improved complexion. According to the company, the Quick-Fix Illuminator is safe for even the most sensitive skin diminishes dark c
- Cynthia Nixon Partners with Galderma and the NRS to Raise Awareness for Rosaceahttps://practicaldermatology.com/news/20130314-cynthia_nixon_partners_with_galderma_and_the_nrs_to_raise_awareness_for_rosacea/2459591/Actress Cynthia Nixon recently joined with dermatologists Rick Fried, MD and Flor Mayoral, MD and a panel of other experts at the "Face to Face with Rosacea: Empowering Professionals and Patients" educational event at the AAD Meeting in Miami. Sponsored by Galderma in conjunction with the National R
- PhotoMedex Launches Three New Neova Productshttps://practicaldermatology.com/news/20130311-photomedex_launches_three_new_neova_products/2459594/Three new Neova products are now available from PhotoMedex. The first is Serious Clarity 4X, an advanced serum with four highly effective brighteners that reverse the appearances of dark spots and skin discolorations. Also available is Illuminating Eye Therapy 4.0, which is designed to combat dark c
- Valeant Launches Acne Scholarship Programhttps://practicaldermatology.com/news/20130311-valeant_launches_acne_scholarship_program/2459598/Valeant Dermatology recently launched a scholarship program entitled, Acanya® I Can Succeed, an initiative that will provide college scholarship money to students who have had acne and have actively tried to address it. The Acanya I Can Succeed Scholarship program will award a total of up to $48,000
- AAD Unveils New App for Diagnosing and Treating Psoriasishttps://practicaldermatology.com/news/20130311-aad_unveils_new_app_for_diagnosing_and_treating_psoriasis/2459599/At its recent annual meeting in Miami, The American Academy of Dermatology introduced a mobile app of evidence-based clinical guidelines for diagnosing and treating psoriasis and psoriatic arthritis. The free app includes a clinical decision tree; reference guide for diagnoses; arthritic diagnostic
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treat
- Skin Cancer Treatments, Cosmetic Procedures Lead Broad Practice Scope of ASDS Membershttps://practicaldermatology.com/news/20130226-skin_cancer_treatments_cosmetic_procedures_lead_broad_practice_scope_of_asds_members/2459607/The 2012 ASDS Survey on Dermatologic Procedures found that dermatologic surgeons performed nearly 8 million medically necessary and cosmetic procedures in the United States in 2012 (a nearly 7 percent increase over 2011), showcasing their extensive training and experience.